Marijuana and the Cannabinoids

Medical and Health Consequences of Marijuana 249
REFERENCES
1. 2004 World Drug Report, United Nations, Office of Drugs and Crime. Oxford University
Press, Oxford, UK.
2. Substance Abuse and Mental Health Services Administration (2004) National Household
Survey on Drug Abuse, Main Findings, 2004, Rockville, MD, US Department of Health
and Human Services.
3. Wagner, F. A. and Anthony, J. C. (2002) From first drug use to drug dependence: developmental
periods of risk for dependence upon marijuana, cocaine, and alcohol.
Neuropsychopharmacology 26, 479–488.
4. 2003 Monitoring the Future, National Survey Results on Drug Use, National Institutes of
Health, Department of health and Human Services; conducted by the University of
Michigan’s Institute for Social Research, National Institute on Drug Abuse, Bethesda,
Maryland. The latest data are available at www.drugabuse.gov.
5. Chen, K. and Kandel, D. B. (1998) Predictors of cessation of marijuana use: an event
history analysis. Drug Alcohol Depend. 50(2), 109–121.
6. Khalsa, J., Genser, S., Francis, H., and Martin, B. R. (2002) Medical and health consequences
of marijuana. J. Clin. Pharmacol. 42 (11, Suppl.), 7s–10s.
7. Mechoulam, R., Parker, L. A., and Gallily, R. (2002) Cannabidiol: An over view of some
pharmacological aspects. J. Clin. Pharmacol. 42 (11, Suppl.), 11s–19s.
8. Hall, W., Solowij, N., and Lemon, J. (1994) The health and psychological consequences of
cannabis use, National Drug Strategy Monograph Series no.25, Canberra; Australian Government
Publishing Service, 1994.
9. Hall, W. and Solowij, N. (1998) Adverse effects of cannabis use. Lancet 352, 1611–1616.
10. Munson, A. E. and Fehr, K. O. (1983) Immunological effects of cannabis, in Cannabis and
Health Hazards, (Fehr K. O. and Kalant H., eds.), Addiction Research Foundation, Toronto,
Canada, pp. 257–253.
11. Hollister, L.E. (1992) Marijuana and immunity. J. Psychoactive Drugs. 24, 159–164.
12. Coates, R. A., Farewell, V. T., Raboud, J., et al. (1990) Cofactors of progression to acquired
immunodeficiency syndrome in a cohort of male sexual contacts of men with human
immunodeficiency virus disease. Am. J. Epidemiol. 132, 717–722.
13. Kaslow, R. A., Blackwelder, W. C., Ostrow, D. G., et al. (1989) No evidence for a role of
alcohol or other psychoactive drugs in accelerating immunodeficiency in HIV-1-positive
individuals. A report from the Multicenter AIDS Cohort Study. JAMA 261(23), 3424–3429.
14. Jones, R. T. (2002) Cardiovascular system effects of marijuana. J. Clin. Pharmacol. 42
(11, Suppl.), 58s–63s.
15. Sidney, S. (2002) Cardiovascular complications of marijuana use. J. Clin. Pharmacol. 42
(11, Suppl.), 64s–70s.
16. Bloom, J. W., Kaltenborn, W. T., Paoletti, P., Camilli, A., and Lebowitz, M. D. (1987)
Respiratory effects of non-tobacco cigarettes. Br. Med. J. Clin. Res. Ed. 295(6612), 1516–
1518.
17. Tashkin, D. P., Fligiel, S., Wu, T. C., et al. (1990) Effects of habitual use of marijuana and/
or cocaine on the lung. NIDA Res. Monogr. 99, 63–87.
18. Tashkin, D. P., Simmons, M. S., Sherrill, D. L., and Coulson, A. H. (1997) Heavy habitual
marijuana smoking does not cause accelerated decline in FEV1 with age. Am. J. Respir.
Crit. Care Med. 155, 141–148.
19. Sherrill, D. L., Kryzanowski, M., Bloom, J. W., and Lebowitz, M. D. (1991) Respiratory
effects of non-tobacco cigarettes: a longitudinal study in general population. Int. J.
Epidemiol. 20, 132–137.
20. Starr, K. and Renneker, M. (1994) A cytologic evaluation of sputum in marijuana smokers.
J. Family Practice 39(4), 359–363.